Skip to content
Triangle logo TriangleGet started
← Study library

NCT00503997 · REGISTRY CONDITION SEARCH

Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2012-05-10

RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pemetrexed together with oxaliplatin may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving pemetrexed together with oxaliplatin works in treating patients with locally advanced head and neck cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Patient Response to Treatment Measured by RECIST Criteria

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
DISEASE CHARACTERISTICS: Inclusion criteria: Patients must meet all of the following criteria in order to be eligible for entry into the trial: * Histologically or cytologically confirmed stage III - IVB HNSCC (includes unknown primary and ParaNasal Sinus cancers)but excludes nasopharyngeal, salivary gland or skin primaries (No TNM staging required) * Patients must have a measurable disease defined by RECIST criteria * Age \> 18 years * ECOG Performance Score of 0, 1 or 2 * Adequate bone marrow as evidenced by: * Absolute neutrophil count \> 1,500/μL * Platelet count \> 100,000/μL * Adequate renal function as evidenced by serum creatinine \< 1.5 mg/dL and CrCl \> 45 mL/min as determined by calculated creatinine clearance using the Cockroft-Gault formula: * CrCl = (140-age) x (weight in kg)/72 x serum creatinine * Multiply by 0.85 (85%) for females * Adequate hepatic function as evidenced by: * Serum total bilirubin \< 1.5 mg/dL * Alkaline phosphatase \< 3X the ULN for the reference lab * SGOT/SGPT \< 3X the ULN for the reference lab * Patients or their legal representatives must be able to read, understand and provide informed consent to participate in the trial. * Patients of childbearing potential and their partners must agree to use an effective form of contraception during the study and for 90 days following the last dose of study medication (an effective form of contraception is an oral contraceptive, double barrier method or surgical intervention resulting in sterility). * Patients must be able to interupt NSAIDs at 2 days before (5 days for long-acting NSAIDs),the day of, and 2 days following administration of Pemetrexed. * Patients must be willing and able to take Folic Acid (350-1000 μg) daily beginning 1 week (7 days) prior to the first dose of Pemetrexed and continued daily until 3 weeks after the last dose of study therapy. In addition, patients must be willing to maintain a Pill Diary as part of study compliance. * Patients must be willing and able to take Vitamin B12 (1000 μg) administered intramuscularly beginning 1 week (7 days) prior to the first dose of Pemetrexed and repeated at the planned End of Treatment visit (no later than 9 weeks from the first injection). * Patients must be willing and able to take Dexamethasone (4 mg of oral or equivalent) that should be given twice daily on the day before, the day of, and the day after each dose of Pemetrexed for rash prophylaxis unless medically contraindicated. Exclusion Criteria: A patient may not be enrolled in the trial if any of the following criteria are met: * Patients with an active infection or with a fever \> 101.30 F within 3 days of the first scheduled day of protocol treatment * History of prior malignancy within the past 3 years except for curatively treated basal cell carcinoma of the skin, cervical intra-epithelial neoplasia, or localized prostate cancer with a current PSA of \< 1.0 mg/dL on 2 successive evaluations, at least 3 months apart, with the most recent evaluation no more than 4 weeks prior to entry * Patients with known hypersensitivity to any of the components of Oxaliplatin and Pemetrexed * Patients who received any chemotherapy, radiation therapy or surgical resection other than diagnostic biopsies for HNSCC prior to the first scheduled day of protocol treatment * Patients who are receiving concurrent investigational therapy or who have received investigational therapy within 30 days of the first scheduled day of protocol treatment(investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication) * Peripheral neuropathy ≥ Grade 2 * Patients who are pregnant or lactating * Any other medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent,cooperate and participate in the study, or interferes with the interpretation of the results. * History of allogeneic transplant * Known HIV (active, previously treated or both) * Presence of clinically detectable (by physical exam) third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. intervention Names
    1. Drug: oxaliplatin
    2. Drug: pemetrexed disodium
    label
    drug therapy
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. drug therapy
    description
    Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery. Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy.
    name
    oxaliplatin
    other Names
    1. Eloxatin
    type
    DRUG
  2. arm Group Labels
    1. drug therapy
    description
    Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery. Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy.
    name
    pemetrexed disodium
    other Names
    1. Alimta
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
42
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    RECIST response categories: Progressive disease (PD): \>=20% increase in sum of longest diameter (LD) of target lesion(s), taking as reference smallest sum LD recorded since treatment started. Complete response (CR): disappearance of all target lesions. Partial response (PR): \>=30% decrease in sum of LD of target lesion(s), taking as reference baseline sum LD. Stable disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD.
    measure
    Patient Response to Treatment Measured by RECIST Criteria
    time Frame
    at 8 weeks
Full study description
brief Summary
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pemetrexed together with oxaliplatin may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving pemetrexed together with oxaliplatin works in treating patients with locally advanced head and neck cancer.
detailed Description
OBJECTIVES: Primary * To evaluate the clinical response rate in patients with locally advanced squamous cell carcinoma of the head and neck treated with neoadjuvant pemetrexed disodium and oxaliplatin. Secondary * To evaluate the pathological complete response in patients who undergo surgical resection or post-induction biopsy. * To assess toxicity of therapy, including the assessment of quality of life, fatigue, and head and neck cancer-related symptoms. * To predict response and toxicities based on pharmacogenomics, genomics, and proteomics. OUTLINE: This is a nonrandomized, open-label study. Patients are assigned to 1 of 2 groups based on resectability of disease (resectable vs nonresectable). * Group I (resectable disease): Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery. After completion of pemetrexed disodium and oxaliplatin, patients undergo surgical resection of disease. * Group II (nonresectable disease): Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy. After completion of pemetrexed disodium and oxaliplatin, patients undergo concurrent chemoradiotherapy. Blood samples are collected at baseline and periodically during study for biomarker and pharmacokinetic studies. Quality of life is assessed prior to each course of therapy and at 4-6 weeks after the last course. After completion of study treatment, patients are followed periodically for up to 3 years.
Source references
references
  1. citation
    Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2014 Nov;25(11):2230-2236. doi: 10.1093/annonc/mdu367. Epub 2014 Jul 31.
    pmid
    25081901
    type
    DERIVED
  2. citation
    Psyrri A, Rampias T, Vermorken JB. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck. Ann Oncol. 2014 Nov;25(11):2101-2115. doi: 10.1093/annonc/mdu265. Epub 2014 Jul 23.
    pmid
    25057165
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-15e71f1efc173953ab81
      requested nct id
      NCT00503997
      primary nct id
      NCT00503997
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      payload sha256
      396791faafa6c44256ba96b5839c5b54dba755c18032dda9ccd8132aaa504806
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-15e71f1efc173953ab81
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00503997
      occurrences
      1. context exact
        NCT00503997
        end
        11
        exact text
        NCT00503997
        start
        0
      offset unit
      unicode_code_points
      query cond
      Laryngeal Cancer
      query disease state id
      ds-laryngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      source json pointer
      /studies/54/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      184b02666cef66c71bd0059ebdef6bc6b1f6ab3f120a4b3c469ec7b6a5371e13
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-1f26b9500c2c4fc3b446
      requested nct id
      NCT00503997
      primary nct id
      NCT00503997
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2598159af8c743c394b8ddc26022f84d68183b09edf878a8af96c931226e93a5
      payload sha256
      9a4b7fe97cee22a624ac1a876981a27805897a21dba040a1341cf3fedae1bd06
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-1f26b9500c2c4fc3b446
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00503997
      occurrences
      1. context exact
        NCT00503997
        end
        11
        exact text
        NCT00503997
        start
        0
      offset unit
      unicode_code_points
      query cond
      Metastatic Squamous Neck Cancer With Occult Primary
      query disease state id
      ds-metastatic-squamous-neck-cancer-with-occult-primary
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-metastatic-squamous-neck-cancer-with-occult-primary-000.json
      source file sha256
      2598159af8c743c394b8ddc26022f84d68183b09edf878a8af96c931226e93a5
      source json pointer
      /studies/12/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      184b02666cef66c71bd0059ebdef6bc6b1f6ab3f120a4b3c469ec7b6a5371e13
    3. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-51963c88a2db4a8da92c
      requested nct id
      NCT00503997
      primary nct id
      NCT00503997
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      payload sha256
      bd67a13d0a86ab5a79d86c955176e3fc0801d630b9db1871bbe8141fd2653d8c
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-51963c88a2db4a8da92c
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00503997
      occurrences
      1. context exact
        NCT00503997
        end
        11
        exact text
        NCT00503997
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hypopharyngeal Cancer
      query disease state id
      ds-hypopharyngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      source json pointer
      /studies/41/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      184b02666cef66c71bd0059ebdef6bc6b1f6ab3f120a4b3c469ec7b6a5371e13

    Preserved source evidence · Not medical advice